Merck CMO sells 10,000 MRK shares at $121.46

Merck & Co., Inc.’s Chief Marketing Officer, Chirfi Guindo, reported an open-market sale of company stock.

Accepted by SEC EDGAR 02/12/2026 - 04:02 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Merck & Co., Inc.’s Chief Marketing Officer, Chirfi Guindo, reported an open-market sale of company stock. On 02/12/2026, he sold 10,000 shares of Merck common stock at a weighted average price of $121.4562 per share, through multiple trades in a narrow price range.

After this transaction, Guindo directly beneficially owned 60,615.127 shares of Merck common stock. The filing notes that detailed trade-by-trade pricing within the $121.4400 to $121.5150 range is available upon request.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Guindo Chirfi

Role Chief Marketing Officer

Sold 10,000 shs ($1.21M)

Share of Position Sold 14.2%

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$121.4562	$1.21M

Holdings After Transaction: Common Stock — 60,615.127 shares (Direct)

Holdings Before and After: Common Stock, 70,615.127 to 60,615.127 shares (Direct)

Other Insiders: 8 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.4400 to $121.5150, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MRK executive Chirfi Guindo report?

Chirfi Guindo reported an open-market sale of 10,000 shares of Merck common stock. The sale occurred on February 12, 2026, at a weighted average price of $121.4562 per share, executed through multiple trades within a narrow price range.

At what price did MRK’s Chief Marketing Officer sell his shares?

The weighted average sale price was $121.4562 per Merck share. The shares were sold in multiple transactions, with individual trade prices ranging from $121.4400 to $121.5150, according to the Form 4 footnote explaining the pricing details.

How many MRK shares does Chirfi Guindo own after this Form 4 sale?

After the reported transaction, Chirfi Guindo beneficially owned 60,615.127 shares of Merck common stock. These shares are reported as directly held, reflecting his remaining ownership position following the 10,000-share open-market sale disclosed.

What role does Chirfi Guindo hold at Merck & Co., Inc. (MRK)?

Chirfi Guindo serves as an officer of Merck & Co., Inc., holding the title of Chief Marketing Officer. The Form 4 identifies his relationship to the issuer as an officer, with no indication that he is a director or 10% owner.

Was the MRK insider sale by Chirfi Guindo a direct or indirect transaction?

The Form 4 classifies the transaction as directly held ownership. The 10,000 shares of Merck common stock sold on February 12, 2026, and the 60,615.127 shares remaining are both reported under direct beneficial ownership, with no intermediary entity disclosed.

Does the MRK Form 4 detail individual trade prices for the 10,000-share sale?

The Form 4 reports only a weighted average price of $121.4562 per share. It states that the 10,000 shares were sold in multiple trades between $121.4400 and $121.5150, and that full trade-by-trade pricing information is available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guindo Chirfi

(Last) (First) (Middle)

MERCK & CO., INC.

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NJ 07065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		S		10,000	D	$121.4562(1)	60,615.127	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.4400 to $121.5150, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

	/s/ Kelly Grez, as attorney-in-fact for Mr. Chirfi Guindo	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.